247 related articles for article (PubMed ID: 12777861)
1. Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses.
Majewski M; Korecka M; Joergensen J; Fields L; Kossev P; Schuler W; Shaw L; Wasik MA
Transplantation; 2003 May; 75(10):1710-7. PubMed ID: 12777861
[TBL] [Abstract][Full Text] [Related]
2. The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: A potential approach to prevention and treatment of posttransplant lymphoproliferative disorders.
Majewski M; Korecka M; Kossev P; Li S; Goldman J; Moore J; Silberstein LE; Nowell PC; Schuler W; Shaw LM; Wasik MA
Proc Natl Acad Sci U S A; 2000 Apr; 97(8):4285-90. PubMed ID: 10759564
[TBL] [Abstract][Full Text] [Related]
3. Prolonged survival of composite facial allografts in non-human primates associated with posttransplant lymphoproliferative disorder.
Barth RN; Nam AJ; Stanwix MG; Kukuruga D; Drachenberg CI; Bluebond-Langner R; Hui-Chou H; Shipley ST; Bartlett ST; Rodriguez ED
Transplantation; 2009 Dec; 88(11):1242-50. PubMed ID: 19996923
[TBL] [Abstract][Full Text] [Related]
4. Everolimus (RAD) inhibits in vivo growth of murine squamous cell carcinoma (SCC VII).
Khariwala SS; Kjaergaard J; Lorenz R; Van Lente F; Shu S; Strome M
Laryngoscope; 2006 May; 116(5):814-20. PubMed ID: 16652094
[TBL] [Abstract][Full Text] [Related]
5. Long-term laryngeal allograft survival using low-dose everolimus.
Lott DG; Dan O; Lu L; Strome M
Otolaryngol Head Neck Surg; 2010 Jan; 142(1):72-8. PubMed ID: 20096226
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamic effects of everolimus on anti-CD3 antibody-stimulated T-lymphocyte proliferation and interleukin-10 synthesis in stable kidney-transplant patients.
Böhler T; Waiser J; Lichter S; Schumann B; Neumayer HH; Kamar N; Budde K
Cytokine; 2008 Jun; 42(3):306-11. PubMed ID: 18440821
[TBL] [Abstract][Full Text] [Related]
7. mTOR inhibition sensitizes gastric cancer to alkylating chemotherapy in vivo.
Cejka D; Preusser M; Fuereder T; Sieghart W; Werzowa J; Strommer S; Wacheck V
Anticancer Res; 2008; 28(6A):3801-8. PubMed ID: 19189667
[TBL] [Abstract][Full Text] [Related]
8. Cyclosporine reduction in the presence of everolimus: 3-month data from a Canadian pilot study of maintenance cardiac allograft recipients.
Ross H; Pflugfelder P; Haddad H; Cantarovich M; White M; Ignaszewski A; Howlett J; Vaillancourt M; Dorent R; Burton JR;
J Heart Lung Transplant; 2008 Feb; 27(2):197-202. PubMed ID: 18267227
[TBL] [Abstract][Full Text] [Related]
9. Complete immunosuppressive withdrawal as a uniform approach to post-transplant lymphoproliferative disease in pediatric liver transplantation.
Hurwitz M; Desai DM; Cox KL; Berquist WE; Esquivel CO; Millan MT
Pediatr Transplant; 2004 Jun; 8(3):267-72. PubMed ID: 15176965
[TBL] [Abstract][Full Text] [Related]
10. Post-transplant lymphoproliferative disorder--the potential of proliferation signal inhibitors.
Pascual J
Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i27-35. PubMed ID: 17456616
[TBL] [Abstract][Full Text] [Related]
11. RAD inhibition of sarcoma growth: implications for laryngeal transplantation.
Knott PD; Tamai H; Strome M; Van Lente F; Shu S
Am J Otolaryngol; 2007; 28(6):375-8. PubMed ID: 17980767
[TBL] [Abstract][Full Text] [Related]
12. Recommendations for use of Certican (everolimus) after heart transplantation: results from a German and Austrian Consensus Conference.
Hummel M
J Heart Lung Transplant; 2005 Apr; 24(4 Suppl):S196-200; discussion S210-1. PubMed ID: 15774322
[TBL] [Abstract][Full Text] [Related]
13. Prolongation of corneal allograft survival by topical application of everolimus in experimental keratoplasty.
Li XQ; Buch G; Otasevic L; Schlickeiser S; Bertelmann E; Pleyer U
Ophthalmic Res; 2008 Oct; 40(6):309-14. PubMed ID: 18688173
[TBL] [Abstract][Full Text] [Related]
14. Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts.
Kneissel M; Luong-Nguyen NH; Baptist M; Cortesi R; Zumstein-Mecker S; Kossida S; O'Reilly T; Lane H; Susa M
Bone; 2004 Nov; 35(5):1144-56. PubMed ID: 15542040
[TBL] [Abstract][Full Text] [Related]
15. Use of everolimus as a rescue immunosuppressive therapy in liver transplant patients with neoplasms.
Gomez-Camarero J; Salcedo M; Rincon D; Lo Iacono O; Ripoll C; Hernando A; Sanz C; Clemente G; Bañares R
Transplantation; 2007 Sep; 84(6):786-91. PubMed ID: 17893613
[TBL] [Abstract][Full Text] [Related]
16. Differential effect of cyclosporine A and SDZ RAD on neointima formation of carotid allografts in apolipoprotein E-deficient mice.
Matsumoto Y; Hof A; Baumlin Y; Hof RP
Transplantation; 2003 Oct; 76(8):1166-70. PubMed ID: 14578747
[TBL] [Abstract][Full Text] [Related]
17. Synergistic effect of vincristine with tacrolimus or sirolimus in prevention of acute heart allograft rejection in the rat.
Jiang W; Jiang J; Xu D; Wang X; Qi S; Ouyang J; Ma A; Vu MD; Bilolo KK; Chen H
Microsurgery; 2003; 23(2):117-22. PubMed ID: 12740883
[TBL] [Abstract][Full Text] [Related]
18. Late acute cardiac allograft rejection: new therapeutic options?
Schweiger M; Wasler A; Prenner G; Tripolt M; Schwarz M; Tscheliessnigg KH
Transplant Proc; 2005 Dec; 37(10):4528-31. PubMed ID: 16387161
[TBL] [Abstract][Full Text] [Related]
19. Tolerability and steady-state pharmacokinetics of everolimus in maintenance renal transplant patients.
Budde K; Neumayer HH; Lehne G; Winkler M; Hauser IA; Lison A; Fritsche L; Soulillou JP; Fauchald P; Dantal J;
Nephrol Dial Transplant; 2004 Oct; 19(10):2606-14. PubMed ID: 15316094
[TBL] [Abstract][Full Text] [Related]
20. A high-capacity quantitative mouse model of drug-mediated immunosuppression based on rejection of an allogeneic subcutaneous tumor.
Hammond-McKibben D; Lake P; Zhang J; Tart-Risher N; Hugo R; Weetall M
J Pharmacol Exp Ther; 2001 Jun; 297(3):1144-51. PubMed ID: 11356940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
